29. Oktober 2026
FDA PDUFA target action date for ILUMYA (tildrakizumab-asmn), a BLA from Sun Pharmaceutical Industries. This is the date by which the FDA is due to act on the application; it can be extended or the decision can come earlier.
FDA-PDUFA-Entscheidungstermine-Kalender